Recommendations for the predictive genetic test in Huntington's disease

Clinical Genetics

Volumn 83, Issue 3, 2013, Pages 221-231

  Macleod, R ^a   Tibben, A ^b   Frontali, M ^c   Evers Kiebooms, G ^d   Jones, A ^e   Martinez Descales, A ^f   Roos, Ra ^b   Bijlsma, Emilia ^e   Blinkenberg, Ellen ^e   Bombard, Yvonne ^e   Borry, Pascal ^e   Craufurd, David ^e   Davis, Mary ^e   De Die Smulders, Christine ^e   Downing, Claudia ^e   Dürr, Alexandra ^e   Garcia Barcina, Maria ^e   Glew, Ruth ^e   Heiberg, Arvid ^e   Heydon, Frances ^e   Hoffman Zacharsk, Dorota ^e   Hösterey Ugander, Ulrika ^e   José Trujillo Tiebas, Maria ^e   Krysa, Wioletta ^e   Liebaers, Inge ^e   Lohkamp, Christiane ^e   Mandich, Paola ^e   Mariotti, Caterina ^e   De Schepper, Bea ^e   Di Maria, Emilio ^e   Nemeth, Andrea ^e   Quarrell, Oliver ^e   Ribaï, Pascale ^e   Semaka, Alicia ^e   Seneca, Sara ^e   Sequeiros, Jorge ^e   Squitieri, Ferdinando ^e   Sulek, Anna ^e   Van Der Meer, Lucienne ^e   Verellen Dumoulin, Christine ^e   De Wert, Guido ^e   Delatycki, Martin ^e   Guttman, Mark ^e   Hayden, Michael ^e   Nance, Martha ^e   Richards, Fiona ^e   Vetter, Louise ^e   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e C/o Huntington's WA ^*

^f Fundacion Jimenez Diaz   (Spain)

Author keywords

Genetic testing; Guidelines; Huntington's disease; Predictive testing

Indexed keywords

ALLELE; ARTICLE; CLINICAL PRACTICE; EUROPE; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; INFORMED CONSENT; MEDICAL INFORMATION; MEDICAL PRACTICE; NEUROLOGIC EXAMINATION; PRACTICE GUIDELINE; PREDICTION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; STANDARD;

GENETIC COUNSELING; GENETIC TESTING; HUMANS; HUNTINGTON DISEASE; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TRUTH DISCLOSURE;

EID: 84874018778     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01900.x     Document Type: Article

References (64)

1. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 1994: 44 (8): 1533-1536.
2. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. J Med Genet 1994: 31: 555-559.
3. Duncan RE, Delayticki MB. Predictive genetic testing in young people for adult-onset conditions: where is the empirical evidence? Clin Genet 2006: 69: 8-16.
4. Duncan RE, Gillam L, Savulescu J, Williamson R, Rogers JG, Delatycki MB. "Holding Your Breath": interviews with young people who have undergone predictive genetic testing for Huntington Disease. Am J of Med Genet 2007: 143A: 1984-1989.
5. Duncan RE, Gillam L, Savulescu J, Williamson R, Rogers JG, Delatycki MB. "You're one of us now": young people describe their experiences of predictive genetic testing for Huntington disease (HD) and familial adenomatous polyposis (FAP). Am J Med Genet (Semin Med Genet) 2008: 148C: 47-55.
6. Borry P, Goffin T, Nys H, Dierickx K. Attitudes regarding carrier testing in incompetent children: a survey of European clinical geneticists. Eur J Hum Genet 2007: 15 (12): 1211-1217.
7. Borry P, Stultiens L, Nys H, Cassiman JJ, Dierickx K. Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet 2006: 70 (5): 374-381.
8. Clarke A. What is at stake in the predictive genetic testing of children? Fam Cancer 2009: 9 (1): 19-22.
9. Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K on behalf of the Public and Professional Policy Committee (PPPC) of the European Society of Human Genetics (ESHG). Genetic testing in asymptomatic minors. Background considerations towards ESHG Recommendations. Eur J Hum Genet 2009: 17 (6): 711-719.
10. Borry P, Evers-Kiebooms G, Cornel MC et al. Genetic testing in asymptomatic minors: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2009: 17 (6): 720-721.
11. OECD Guidelines for Quality Assurance in Molecular Genetic Testing, from http://www.oecd.org/dataoecd/43/6/38839788.pdf.
12. Holzmann C, Saecker AM, Epplen JT, Riess O. Avoiding errors in the diagnosis of (CAG)n expansion in the huntingtin gene. Med Genet 1997: 34 (3): 264.
13. Yu S, Fimmel A, Fung D, Trent RJ. Polymorphisms in the CAG repeat-a source of error in Huntington disease DNA testing. Clin Genet 2000: 58 (6): 469-472.
14. Losekoot M, Bakker B, Laccone F, Stenhouse S, Elles R. A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease. Eur J Hum Genet 1999: 7 (2): 217-222.
15. ACMG/ASHG Statement. Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 1998: 62: 1243-1247.
16. Bombard Y, Penziner E, Decolongon J et al. Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation. Clin Genet 2007: 71 (3): 220-231.
17. Benjamin CM, Adam S, Wiggins S et al. Proceed with care: direct predictive testing for Huntington disease. Am J Hum Genet 1994: 55 (4): 606-617.
18. Maat-Kievit A, Losekoot M, Zwinderman A et al. Predictability of age at onset in Huntington disease in the Dutch population. Medicine 2002: 81 (4): 251-259.
19. Gutierrez MC, MacDonald AS. Huntington's disease, critical illness insurance and life insurance. Scand Actuarial J 2004: 279: 311.
20. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, on behalf of an International Huntington's Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004: 65 (4): 267-277.
21. Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 2010: 153B (2): 397-408.
22. Gayán J, Brocklebank D, Andresen JM et al. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet Epidemiol 2008: 32: 445-453.
23. Li XJ, Friedman M, Li S. Interacting proteins as genetic modifiers of Huntington disease. Trends Genet 2007: 23: 531-533.
24. van Dellen A, Grote HE, Hannan AJ. Gene-environment interactions. Neuronal dysfunction and pathological plasticity in Huntington's disease. Clin Exp Pharmacol Physiol 2005: 32: 1007-1019.
25. Nithianantharajah J, Barkus C, Murphy M, Hannan AJ. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis 2008: 29: 490-504.
26. Leeflang EP, Zhang L, Tavare S et al. Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. Hum Mol Genet 1995: 4: 1519-1526.
27. Chong SS, Almqvist H, Telenius L et al. Contribution of DNA sequence and CAG Size to mutation frequencies of intermediate alleles for huntington disease: evidence from single sperm analyses. Hum Mol Genet 1997: 6: 301-309.
28. Goldberg YP, McMurray CT, Zeisier J et al. Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum Mol Genet 1995: 4: 1911-1918.
29. Semaka A, Collins JA, Hayden MR. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). Am J Med Genet B Neuropsychiatr Genet 2010: 153B (1): 314-320.
30. Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet 2006: 70: 283-294.
31. Costa M, Magalhães P, Guimarães L, Maciel P, Sequeiros J, Sousa A. The CAG repeat at the Huntington disease gene in the Portuguese population: insights into its dynamics and to the origin of the mutation. J Hum Genet 2006: 51: 189-195.
32. Costa M, Magalhães P, Ferreirinha F et al. Molecular diagnosis of Huntington disease in Portugal: implications for genetic counselling and clinical practice. Eur J Hum Genet 2003: 11: 872-878.
33. Duisterhof M, Trijsburg RW, Niermeijer MF, Roos RA, Tibben A. Psychological studies in Huntington's disease: making up the balance. J Med Genet 2001: 38: 852-856.
34. Almqvist EW, Brinkman RR, Wiggins S, Hayden MR. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clin Genet 2003: 64 (4): 300-309.
35. Timman R, Roos R, Maat-Kievit A, Tibben A. Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychol 2004: 23: 189-197.
36. Hayden MR, Bombard Y. Psychosocial effects of predictive testing for Huntington's disease. Adv Neurol 2005: 96: 226-239.
37. Decruyenaere M, Evers-Kiebooms G, Cloostermans T et al. Psychological distress in the 5-year period after predictive testing for Huntington's disease. Euro J Hum Genet 2003: 11: 30-38.
38. Decruyenaere M, Evers-Kiebooms G, Boogaerts A et al. Predictive testing for Huntington's disease: relationship with partners after testing. Clin Genet 2004: 65: 24-31.
39. Gargiulo M, Lejeune S, Tanguy M-L et al. Long-term outcome of presymptomatic testing in Huntington disease. Eur J Hum Genet 2009: 17 (2): 165-171.
40. Bombard Y, Palin J, Friedman JM et al. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. Am J Med Genet Part B Neuropsychiatr Genet 2012: 159B: 217-226.
41. Williams JK, Erwin C, Juhl AR et al. In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet 2010: 153B: 1150-1159.
42. Bombard Y, Penziner E, Suchowersky O et al. Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. Eur J Hum Genet 2008: 16: 279-289.
43. Bombard Y, Veenstra G, Friedman JM et al. Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ 2009: 338: b2175.
44. Bombard Y, Palin J, Friedman JM. Factors associated with experiences of genetic discrimination among individuals at risk for Huntington disease. Am J Med Genet 2011: 156B (1): 19-27.
45. Evers-Kiebooms G, Nys K, Harper P et al. Predictive DNA-testing for Huntington's disease and reproductive decision making: a European collaborative study. Eur J Hum Genet 2002: 10: 167-176.
46. Simpson SA, Zoeteweij M, NyS K et al. Prenatal testing for Huntington's disease: a European collaborative study. Eur J Hum Genet 2002: 10: 689-693.
47. Tassicker R, Savulescu J, Skene L, Marshall P, Fitzgerald L, Delatycki MB. Prenatal diagnosis requests for Huntington's disease when the father is at risk and does not want to know his genetic status: clinical, legal, and ethical viewpoints. BMJ 2003: 326 (7384): 331-333.
48. Erez A, Plunkett K, Sutton VR, McGuire AL. The right to ignore genetic status of late onset genetic disease in the genomic era; Prenatal testing for Huntington disease as a paradigm. Am J Med Genet A 2010: 152A (7): 1774-1780.
49. Duncan RE, Foddy B, Delatycki MB. Refusing to provide a prenatal test: can it ever be ethical? BMJ 2006: 333 (7577): 1066-1068.
50. Soini S, Ibarreta D, Anastasiadou V et al. The interface between medically assisted reproduction and genetics: technical, social, ethical and legal issues. Eur J Hum Genet 2006: 14: 588-645.
51. Bustamante-Aragones A, Trujill-Tiebas MJ, Gallego-Merlo J et al. Prenatal diagnosis of Huntington disease in maternal plasma: direct and indirect study. Eur J Neurol 2008: 15 (12): 1338-1344.
52. Sermon K, Goossens V, Seneca S et al. Preimplantation diagnosis for Huntington's disease: clinical application and analysis of the HD expansion in affected embryos. Prenat Diagn 1998: 18: 1427-1436.
53. Lashwood A, Flinter F. Clinical and counselling implications of preimplantation genetic diagnosis for Huntington's disease in the UK. Hum Fertil 2001: 4 (4): 235-238.
54. Thornhill AR, deDie-Smulders CE, Geraedts JP et al. ESHRE PGD Consortium 'Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)'. Hum Reprod 2005: 20 (1): 35-48.
55. Sermon K, De Rijcke M, Lissens W et al. Preimplantation genetic diagnosis for Huntington's disease with exclusion testing. Eur J Hum Genet 2002: 10 (10): 591-598.
56. Braude PR, De Wert GM, Evers Kiebooms G, Pettigrew RA, Geraedts JP. Non-disclosure preimplantation genetic diagnosis for Huntington's disease: practical and ethical dilemmas. Prenat Diagn 1998: 18 (13): 1422-1426.
57. Stern HJ, Harton GL, Sisson ME et al. Non-disclosing preimplantation genetic diagnosis for Huntington disease. Prenat Diagn 2002: 22: 503-507.
58. Fecke W, Gianfriddo M, Gaviraghi G, Terstappen GC, Heitz F. Small molecule drug discovery for Huntington's disease. Drug Discov Today 2009: 14: 453-464.
59. Mason SL, Barker RA. Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs 2009: 14: 273-297.
60. http://www.hdsa.org/research/therapies-in-pipeline.html
61. Paulsen JS, Nopoulos PC, Aylward E et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010: 82 (3- 4): 201-207.
62. Biglan KM, Ross CA, Langbehn DR et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord 2009: 24: 1763-1772.
63. Klöppel S, Chu C, Tan GC et al. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurol 2009: 72: 426-431.
64. Tabrizi SJ, Langbehn DR, Leavitt BR et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009: 8: 791-801.